People with Type 2 diabetes should be concerned with their kidney function, but current testing is woefully insufficient. A ...
Zacks Investment Research on MSN
Will BDTX's EGFR Inhibitor Bring a Paradigm Shift in NSCLC Treatment?
Black Diamond Therapeutics’ BDTX lead clinical-stage program, silevertinib (formerly BDTX-1535), is a brain penetrant, fourth ...
Nefecon, an oral targeted-release formulation of budesonide that targets drug release into the distal ileum, provided significant improvements in the loss of kidney function in patients with ...
“These compelling overall survival results from the FLAURA2 trial confirm osimertinib plus chemotherapy as the first-line standard of care in EGFR - [mutant] advanced non-small cell lung cancer,” said ...
Study findings support intensive blood pressure control in patients with hypertension without chronic kidney disease at baseline.
A novel antibody-drug conjugate (ADC), iza-bren (BL-B01D1), demonstrated encouraging safety and efficacy results in previously treated patients with EGFR-mutated non-small cell lung cancer (NSCLC), ...
MedPage Today on MSN
Ivonescimab Delays Lung Cancer Progression in EGFR-Mutated Disease
A dding ivonescimab to chemotherapy prolonged progression-free survival (PFS) in previously treated advanced EGFR -mutant non-small cell lung cancer (NSCLC), but failed to significantly improve ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback